Evidence map›Paper›PMID 40037339›Full record

ArticleThe Journal of infectious diseases2025

Viral and Immune Factors Associated With COVID-19 Outcome in the C3PO Trial of Convalescent Plasma.

Clara Di Germanio, Erika G Marques de Menezes, Robert Clevenger, Ian Rines, Valerie L Durkalski-Mauldin, Eric Leifer, Sharon Yeatts, Xutao Deng, Brendan G Balasko, John F McDyer and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Clara Di GermanioVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0002-6047-211X
Erika G Marques de MenezesVitalant Research Institute, San Francisco, California, USA.
Robert ClevengerDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Ian RinesDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Valerie L Durkalski-MauldinDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Eric LeiferNational Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland, USA.ORCID 0000-0001-6888-8307
Sharon YeattsDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID 0000-0001-9235-0670
Xutao DengVitalant Research Institute, San Francisco, California, USA.
Brendan G BalaskoVitalant Research Institute, San Francisco, California, USA.
John F McDyerDepartment of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Leilani MontalvoVitalant Research Institute, San Francisco, California, USA.
Daniel ChafetsVitalant Research Institute, San Francisco, California, USA.
Nadine N TaliaDepartment of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-0891-542X
Alexandra WeissmanDepartment of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-3350-899X
Sumith R PanickerNational Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland, USA.
Yogen KanthiNational Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland, USA.
Mars StoneVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-5619-2767
Frederick K KorleyDepartment of Emergency Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Clifton W CallawayDepartment of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Philip J NorrisVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0003-0526-2088

Funding

ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7M
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Clinical Coordinating Center (CCC)U24NS100659 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILLIAM G BARSAN, Clifton W. Callaway · 2017 to 2026
$6.4M
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Data Coordinating CenterU24NS100655 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI VALERIE L DURKALSKI, Sharon Dziuba Yeatts · 2017 to 2026
$4.4M
Biomedical Advanced Research and Development AuthorityDepartment ofHealth and Human Services 75A50120C00094NHLBI NIH HHS OT2 HL156812NIH HHS 1OT2HL156812NIH HHS 1OT2HL156812-01NIH HHS U24NS100655NIH HHS U24NS100659NINDS NIH HHS U24 NS100655NINDS NIH HHS U24 NS100659
6 · The paper itself

Abstract

We examined innate and antibody responses in C3PO clinical trial participants of coronavirus disease 2019 (COVID-19) convalescent plasma to identify predictors of disease progression. We found severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viremia in 64% of participants at enrollment, and we could also quantify viremia in approximately half of those samples using an RT-PCR assay. Viremia was associated with increased risk of disease progression (OR, 3.0; 95% CI, 1.7-5.0). Participants with viremia at baseline had lower SARS-CoV-2 binding antibody levels and higher proinflammatory cytokine levels, including IP-10 (CXCL10), TNF-α, calprotectin, and CRP. Disease progression correlated with extracellular vesicle levels from multiple cell types in the convalescent but not acute phase of the disease. Male sex predicted worse disease outcome and was associated with higher baseline levels of several proinflammatory cytokines. Viremia's strong predictive value for disease progression argues for further study of its use to predict which patients with COVID-19 might require more intensive therapy or monitoring.

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2AdultCOVID-19 SerotherapyCytokinesDisease ProgressionFemaleHumansImmunization, PassiveMaleMiddle AgedTreatment OutcomeViremiaAntibodies, ViralCytokinesconvalescent plasmacytokinesextracellular vesiclesSARS-CoV-2viremia

Identifiers

PMID40037339
PMCPMC12128084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.